mynth
01/2026100%LBO

Optum UK acquired by TPG

UNITED KINGDOM Healthcare Services / Health Tech EV £1–10bn

Context

TPG is in advanced negotiations to acquire Optum UK from UnitedHealth Group. This transaction follows UnitedHealth’s relatively short ownership of the asset, which it acquired in 2023 after an intensive regulatory review by the UK Competition and Markets Authority. The sale process, managed by Bank of America, attracted significant interest from top-tier private equity firms, including Blackstone, reflecting the asset’s status as a high-quality infrastructure-like software provider. The strategic rationale for TPG is a clear "buy-and-build" play, as the firm intends to explore a merger between Optum UK and Nextech, its US-based electronic medical record software provider. Such a combination would create a transatlantic leader in healthcare IT, allowing for the cross-pollination of software features and a broader geographical footprint. For UnitedHealth, the divestment is viewed as a strategic move to optimize its portfolio and improve group valuation by offloading a business that, while dominant in its local market, faced significant regulatory scrutiny regarding vertical integration. The deal is expected to close in early 2026, subject to final negotiations and potential updated reviews by UK health and competition authorities, given the critical nature of the EPR systems provided to the NHS.

The acquisition of Optum UK is part of the growth strategy of TPG, which already has several external growth operations under its belt, notably A-Gas in 2023.

Optum UK, which reported an EBITDA margin of [members only] in 2025, is valued in this transaction at an EV/EBITDA multiple of Above 20x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Optum UK, primarily comprising the operations of EMIS Group, is the leading provider of healthcare software and electronic patient record (EPR) systems in the United Kingdom. The company’s core business model focuses on supplying mission-critical technology infrastructure to the majority of Britain’s general practitioners (GPs), as well as community pharmacies and hospital departments. Its value proposition centers on the seamless management of clinical data, enabling healthcare professionals to access real-time patient information, streamline administrative workflows, and improve diagnostic accuracy. The group’s strategy is built on high levels of recurring revenue through long-term contracts with the National Health Service (NHS) and related healthcare providers. By acting as the digital backbone of primary care in the UK, Optum UK plays a vital role in the national healthcare ecosystem, facilitating the integration of patient care across different clinical settings and supporting the digital transformation of public health services through advanced data analytics and interoperable software solutions.

Ent. Value

£1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

4x–10x

EV / EBITDA

Above 20x

EV / EBIT

[members only]

Historical Financials (GBP)

Year
Rev
EBITDA
EBIT
2025
£100–200M
£50–100M
[members only]
2024
£100–200M
£50–100M
[members only]

Other operations with TPG

Other operations with TPG
DateAcquirerTargetCountrySector
09/2023TPGA-GASUNITED KINGDOMHazardous Waste
07/2022TPGDOC GENERICIITALYGenerics / Labs
04/2021TPGTHE MADE GROUPAUSTRALIADairy
11/2014TPGPREZZOUNITED KINGDOMRestaurants / Chains

Similar deals in Healthcare Services

Similar deals in Healthcare Services
DateAcquirerTargetCountrySector
03/2026THERMO FISHER SCIENTIFICCLARIO HOLDINGSUNITED STATESCRO / Clinical Trials
03/2026RADNETGLEAMERFRANCEHealth Tech
01/2026PERMIRACARNE GROUPIRELANDHealthcare Services
01/2026ANTIN INFRASTRUCTUREEMSERENETHERLANDSCRO / Clinical Trials
01/2026SAGARDQUIPMENTFRANCEHealthcare Services
12/2025PHARMA EQUITY GROUPOTIOMDENMARKHealth Tech
11/2025EURAZEOEXCELYAFRANCECRO / Clinical Trials
11/2025ASKER HEALTHCARE GROUPFINMED GROUPFRANCEHospital Logistics
10/2025EVOLEMAPPERTONFRANCESterilization & Hygiene
05/2025FIVE ARROWSHUBLOFRANCEHealth Tech

REFERENCES

Valuation range: EV £1–10bn

Revenue range: £100–200M

EBITDA range: £50–100M

EV/Revenue range: 4x - 10x

EV/EBITDA range: Above 20x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Optum UK by TPG are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: optum uk

FAQ

What transaction does this page cover?

This page covers TPG’s acquisition of 100% of Optum UK, a British company specialised in Health Tech, in 2026, structured as a leveraged buyout (LBO).

How was the acquisition of Optum UK by TPG valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the £1–10bn band, its EV/EBITDA multiple within the Above 20x range, and its EV/revenue multiple within the 4x - 10x range. Exact figures are available to members.

What were Optum UK’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Optum UK generated annual revenue estimated in the £100–200M range and EBITDA in the £50–100M bracket (FY 2025). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.